Skip to Content

Join the 'von Willebrand's Disease' group to help and get support from people like you.

von Willebrand's Disease News

Vonvendi Approved to Control Bleeding Disorder

Posted 12 Dec 2015 by Drugs.com

TUESDAY, Dec. 8, 2015 – Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder. VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that's essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth. Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release. Vonvendi is produced by Baxalta, based in Westlake Village, Calif. More information Visit the FDA to learn more. Read more

Related support groups: von Willebrand's Disease, Vonvendi, Von Willebrand Factor (recombinant)

FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Posted 10 Dec 2015 by Drugs.com

December 8, 2015 – The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD. VWD is the most common inherited bleeding disorder, affecting approximately 1 percent of the U.S. population. Men and women are equally affected by VWD, which is caused by a deficiency or defect in von Willebrand factor, a protein that is critical for normal blood clotting. Patients with VWD can develop severe bleeding from the nose, gums, and intestines, as well as into muscles and joints. Women with VWD may have heavy menstrual periods lasting longer than average and may experience excessive ... Read more

Related support groups: von Willebrand's Disease, Von Willebrand Factor, Von Willebrand Factor (recombinant), Vonvendi

Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Posted 9 Dec 2009 by Drugs.com

HOBOKEN, N.J., Dec. 7 /PRNewswire/ – Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD). Wilate is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD, including pediatric patients, in four prospective clinical trials utilizing both objective and subjective criteria. Wilate is indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe VWD as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.(1) Wilate is the first double virus inactivated VWF/FVIII (von Willebrand Factor / ... Read more

Related support groups: von Willebrand's Disease

Ask a Question

Further Information

Related Condition Support Groups

Coagulation Defects and Disorders

Related Drug Support Groups

desmopressin, DDAVP, von willebrand factor, Stimate, Wilfactin, Vonvendi, Alphanate, Wilate, Haemate P, Humate-P, Wilstart, antihemophilic factor / von willebrand factor, Optivate